Exelixis (EXEL) reported Q4 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $423.9 million versus the consensus estimate of $416.94 million.
GUIDANCE:
Exelixis sees FY2024 revenue of $1.775-1.875 billion, versus the consensus of $1.84 billion.
2023 Financial Guidance
Exelixis is maintaining the previously provided financial guidance for fiscal year 2023:
Total revenues |
| $1.775 billion - $1.875 billion |
Net product revenues |
| $1.575 billion - $1.675 billion |
Cost of goods sold |
| 4.0% - 5.0% of net product revenues |
Research and development expenses (1) |
| $1,000 million - $1,050 million |
Selling, general and administrative expenses (2) |
| $475 million - $525 million |
Effective tax rate |
| 20% - 22% |
____________________ | ||
(1) | Includes $45 million of non-cash stock-based compensation expense. | |
(2) | Includes $55 million of non-cash stock-based compensation expense. | |
|